DEVELOPMENT CENTER FOR BIOTECHNOLOGY / Taiwan
Healthcare+ Expo Booth:L309a
The DCB develops new drugs either independently or collaboratively with academia and industry. To date, the DCB has obtained over 10 investigational New Drug application approvals and has successfully transferred to industry through licensing. Accordingly ,these drugs are under development through clinical trials. DCB can perform commissioned research on developing new drugs and offer customized services to help accelerate commercialization of new drugs.
 
Established1984
Registered CapitalTWD 0
Employees0
Product/Service Category
Cell therapy Bio-Pharmaceutical Logistic service for bio/medical industry Academia & R&D institutes
As a Buyer
Design and Manufacture of the 3rd Generation Lentiviral Vectors for Cell Therapy
Low Immunogenic Induced Pluripotent Stem Cell Platform For Degenerative Diseases
As a Supplier
Design and Manufacture of the 3rd Generation Lentiviral Vectors for Cell Therapy
High Yield CHO-C Expression System
Highly Selective FLT3 Kinase Inhibitor as anti-AML Drug
Development of Anti-CD73 Antibody for Cancer Immunotherapy
Drug Metabolism & Pharmacokinetics study
Pharmacology Study
Toxicology Study
Drug Analysis & Formulation
Pharmaceutical Synthesis Platform Technology
Pharmaceutical Process Development
In vitro Biological Activity Screening for Anticancer Drugs
Safety Pharmacology
Protein Drug Discovery and Development
Protein Drug Characterization
Protein Drug Functional Study
Products
Chinese hamster ovary (CHO) cell line is the major host cell for the manufacturing of pharmaceutical biologics. The proprietary CHO cell line with intellectual property is highly required in the biotech companies for biologics product production. We developed a high yield CHO cell expression system, named CHO-C platform, including a proprietary CHO cell line and proprietary expression plasmids. The mAb productivity in the CHO-C platform was about 1.5-2 fold better than that in the CHO-S/pCHO1.0 system. The stability of the CHO-C cell can be maintained over 120 generations. In addition, the quality of mAb produced from CHO-C cells was comparable to benchmark control. Altogether, the CHO-C platform is a competitive and valuable mammalian expression system for biologics production.

Application areas
CHO-C is the first own-brand CHO system in Asia-Pacific. The expression level is comparable to global companies.
We can provide CLD worldwide.
Features/Strengths
CHO is the preferred host for the production of biopharmaceutics
1. Able to produce complex therapeutics
2. Manufacturing adaptability
3. 94 % of FDA approved mAbs are made from CHO cells (2017~2020)
4. The global market for mAbs is expected to be USD 350 billion by 2027.
Product/Service Category
Bio-Pharmaceutical
Product supporting document, if any
CHO-C platform.pdf
Technology/pipeline/platform
DCBCO1901 with a novel chemical structure exhibits highly potent and selective inhibitory activity against FLT3 as well as its mutants. DCBCO1901 exhibits selective cytotoxicity and effectively suppresses the intracellular FLT3 signaling in AML cell lines harboring the FLT3 mutant. Once-daily oral administration of DCBCO1901 completely suppresses FLT3-ITD mutant tumor growth in a xenograft model and PDX model. Hence, DCBCO1901 can be a precision medicine for treating cancer patients with FLT3 mutation.
Application areas
The precision medicine approaches for patients with acute myeloid leukemia (AML).
Features/Strengths
1. Patentable and orally active small molecule inhibitor exhibits highly potent and selective inhibitory activity against FLT3
as well as its mutants.
2. Precise medication for the treatment of AML patients with FLT3 mutant.
Product/Service Category
Bio-Pharmaceutical
Product supporting document, if any
FLT3 inhibitor-non-confidential slide deck.pdf
Services
1. Pharmaceutical Synthesis Platform Technology

2. Pharmaceutical process development

3. In vitro biological activity screening for Anticancer drugs

4. Safety Pharmacology

5. In vitro activity mechanism test

6. Caco-2 permeability assay
Application areas
Chemistry Services Analysis and Synthesis
Features/Strengths
Providing Co-development strategies.
• For companies with good drug targets, we provide a cooperation model for drug design
• Academic units with preliminary research and development results are willing to cooperate with us in the development
• Provide a diversified source of drugs and jointly develop drugs
Product/Service Category
Bio-Pharmaceutical
Product supporting document, if any
生技中心 化藥所_DM 1090924-1.pdf
1. Protein Drug Discovery and Development

2. Protein Drug Characterization

3. Protein Drug Functional Study
Application areas
Service for Protein Drug Development
Features/Strengths
One-Stop Service for Protein Therapeutics
Product/Service Category
Bio-Pharmaceutical
1. Pharmacology Study

2. Drug Analysis & Formulation

Application areas
Service for New Drug development
Features/Strengths
One Stop-shop for New Drug Preclinical Development
Product/Service Category
Bio-Pharmaceutical
Product supporting document, if any
DCB平台所服務能量 2021版.pdf
Latest B2B Information
Products you might be interested
Companies you might be interested
© Institute for Biotechnology and Medicine Industry & Research Center for Biotechnology and Medicine Policy
Contact Us
Loading...